FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1361-1364 September 23, 2004 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Tegaserod (Zelnorm, Novartis Pharmaceuticals) is a partial serotonin 5-hydroxytryptamine₄ (5-HT₄)–receptor agonist approved by the Food and Drug Administration (FDA) for the short-term treatment of constipation-predominant irritable bowel syndrome in women. From the initiation of marketing, in August 2002, through March 2004, the FDA MedWatch system received 20 spontaneous reports of cases of ischemic colitis associated with the use of tegaserod. These reports were first identified by two of us and classified as ischemic colitis on the basis of clinical symptoms, features on lower gastrointestinal endoscopy, histopathologic examination of the colon, and intestinal surgery, in accordance with . . . [Full Text of this Article]

This article has been cited by other articles:

• Lembo, A. J. (2006). A 54-Year-Old Woman With Constipation-Predominant Irritable Bowel Syndrome. JAMA 295: 925-933 [Full Text]  
• Farthing, M. J G (2005). Treatment of irritable bowel syndrome. BMJ 330: 429-430 [Full Text]